The increased enzymatic activity of the CYP2C9 during higher degrees of NAFLD progression related with the increased hypoxia-induced factor-1alpha expression in NAFLD’s late stage [313]. Here, CYP2C9 is linked to metabolic dysfunction-associated steatotic liver disease.